| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $92,011,840 | 46 | 100 |
| Kramer Kelly A. | director | 0 | $0 | 2 | $713,186 | $-713,186 |
| Bluestone Jeffrey | director | 0 | $0 | 3 | $1.97M | $-1.97M |
| WELTERS ANTHONY | director | 0 | $0 | 1 | $2.68M | $-2.68M |
| Dickinson Andrew D | Chief Financial Officer | 0 | $0 | 12 | $4.85M | $-4.85M |
| Telman Deborah H | EVP, Corporate Affairs & GC | 0 | $0 | 1 | $6.59M | $-6.59M |
| Mercier Johanna | Chief Commercial Officer | 0 | $0 | 12 | $18.64M | $-18.64M |
| O'Day Daniel Patrick | Chairman & CEO | 0 | $0 | 15 | $56.58M | $-56.58M |
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 …
Over the last 12 months, insiders at Gilead Sciences, Inc. have bought $0 and sold $92.01M worth of Gilead Sciences, Inc. stock.
On average, over the past 5 years, insiders at Gilead Sciences, Inc. have bought $0 and sold $39.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $2M was made by WOLD OLSEN PER (director) on 2015‑02‑06.
| 2026-11-02 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $169.74 | $2.55M | -1.68% | |
| 2026-10-30 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,881 0.0013% | $175.25 | $2.78M | -1.04% | |
| 2026-10-15 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $156.22 | $468,660 | +0.84% | |
| 2026-10-15 | Sale | Mercier Johanna | Chief Comm & Corp Aff Officer | 3,000 0.0002% | $156.22 | $468,660 | +0.84% | |
| 2026-10-01 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $147.90 | $2.22M | +5.79% | |
| 2026-09-15 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $145.29 | $435,870 | +3.47% | |
| 2026-09-15 | Sale | Mercier Johanna | Chief Comm & Corp Aff Officer | 3,000 0.0002% | $144.22 | $432,646 | +3.47% | |
| 2026-09-01 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $148.64 | $2.23M | +1.10% | |
| 2026-08-26 | Sale | WELTERS ANTHONY | director | 18,000 0.0015% | $148.62 | $2.68M | +2.13% | |
| 2026-08-20 | Sale | Bluestone Jeffrey | director | 5,000 0.0004% | $145.02 | $725,078 | +5.25% | |
| 2026-08-17 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $138.36 | $415,080 | +8.36% | |
| 2026-08-17 | Sale | Mercier Johanna | Chief Comm & Corp Aff Officer | 28,000 0.0022% | $137.64 | $3.85M | +8.36% | |
| 2026-08-03 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $130.31 | $1.95M | +13.43% | |
| 2026-07-15 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $129.93 | $389,777 | +12.10% | |
| 2026-07-15 | Sale | Mercier Johanna | Chief Comm & Corp Aff Officer | 3,000 0.0002% | $129.92 | $389,758 | +12.10% | |
| 2026-07-01 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $126.29 | $1.89M | +16.23% | |
| 2026-06-15 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $125.40 | $376,200 | +17.06% | |
| 2026-06-15 | Sale | Mercier Johanna | Chief Comm & Corp Aff Officer | 3,000 0.0002% | $123.92 | $371,762 | +17.06% | |
| 2026-06-01 | Sale | O'Day Daniel Patrick | Chairman & CEO | 15,000 0.0012% | $131.46 | $1.97M | +10.14% | |
| 2026-05-15 | Sale | Dickinson Andrew D | Chief Financial Officer | 3,000 0.0002% | $132.27 | $396,810 | +5.91% |
| MARTIN JOHN C | director | 2877762 0.2321% | $481.94M | 1 | 157 | +15.04% |
| MILLIGAN JOHN F | President and CEO | 1165924 0.094% | $195.26M | 1 | 53 | +12.51% |
| WOLD OLSEN PER | director | 97854 0.0079% | $16.39M | 4 | 3 | +18.83% |
| HILLS CARLA A | director | 2742 0.0002% | $459,202.74 | 2 | 0 | <0.0001% |
$1,927,310,793 | 31 | 28.02% | $1,325.87B | |
$364,368,632 | 29 | 9.65% | $36.8B | |
$6,224,380 | 25 | 3.58% | $640.75B | |
$23,541,811 | 22 | 6.43% | $126.14B | |
$28,542,809 | 19 | 26.39% | $505.4B |
| Increased Positions | 1,203 | +58.71% | 80M | +7.46% |
| Decreased Positions | 884 | -43.14% | 62M | -5.77% |
| New Positions | 304 | New | 14M | New |
| Sold Out Positions | 118 | Sold Out | 4M | Sold Out |
| Total Postitions | 2,368 | +15.57% | 1B | +1.69% |
| Vanguard Group Inc | $14.47M | 9.59% | 118.98M | -380,582 | -0.32% | 2025-09-30 |
| Blackrock, Inc. | $14.14M | 9.37% | 116.28M | +1M | +1.22% | 2025-09-30 |
| Fmr Llc | $7.33M | 4.86% | 60.32M | +360,902 | +0.6% | 2025-09-30 |
| State Street Corp | $7.19M | 4.76% | 59.09M | -98,855 | -0.17% | 2025-09-30 |
| Capital World Investors | $5.49M | 3.64% | 45.18M | -1M | -2.43% | 2025-09-30 |
| Dodge & Cox | $3.66M | 2.43% | 30.13M | -685,191 | -2.22% | 2025-09-30 |
| Capital Research Global Investors | $3.65M | 2.42% | 30.01M | -1M | -3.48% | 2025-09-30 |
| Geode Capital Management, Llc | $3.64M | 2.41% | 29.93M | +721,324 | +2.47% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $3.22M | 2.14% | 26.5M | +3M | +12.37% | 2025-09-30 |
| Wellington Management Group Llp | $3.12M | 2.06% | 25.62M | -12M | -31.74% | 2025-09-30 |